Lupin gets 6 observations from USFDA for its Pithampur Unit-2
NEW DELHI: Drug firm Lupin Saturday said the US health regulator has issued six observations after the inspection of a unit of its Pithampur facility in Madhya Pradesh.
The inspection of Pithampur Unit -2 was carried out by the United States Food and Drug administration (USFDA) between January 14 and January 25, 2019,
Lupin said in a statement.
"The inspection at Pithampur Unit-2 (Indore) closed with 6 observations," it added.
The company, however, did not provide any details about the nature of the observations.
The company is confident of addressing the observations satisfactorily, Lupin said.
The US health regulator issues observations by means of a FDA Form 483 notifying the company's management of objectionable conditions at the facility inspected.
The inspection of Pithampur Unit -2 was carried out by the United States Food and Drug administration (USFDA) between January 14 and January 25, 2019,
Lupin said in a statement.
"The inspection at Pithampur Unit-2 (Indore) closed with 6 observations," it added.
The company, however, did not provide any details about the nature of the observations.
The company is confident of addressing the observations satisfactorily, Lupin said.
The US health regulator issues observations by means of a FDA Form 483 notifying the company's management of objectionable conditions at the facility inspected.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd